SCHEMBL20951081

SCHEMBL20951081

CN1CCC(Sc2cc(C(=O)O)ccn2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM2B Q8NHM5 3/20 0.54
▸ WNT1 P04628 4/20 0.52
▸ GSK3B P49841 4/20 0.52
▸ DYRK1A Q13627 4/20 0.52
▸ DDB1 Q16531 3/20 0.51
▸ CRBN Q96SW2 3/20 0.51
▸ JMJD6 Q6NYC1 1/20 0.45
▸ PIK3CA P42336 1/20 0.41
▸ KDM4C Q9H3R0 4/20 0.41
▸ KDM5A P29375 3/20 0.41
▸ KDM5B Q9UGL1 3/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ KDM6B O15054 2/20 0.41
▸ KDM5C P41229 2/20 0.41
▸ KDM2A Q9Y2K7 2/20 0.41
▸ KDM3A Q9Y4C1 2/20 0.41
▸ KDM4A O75164 2/20 0.41
▸ TET3 O43151 1/20 0.41
▸ BBOX1 O75936 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29630836 0.87 DDB1 (0.59) KDM2BWNT1GSK3BDYRK1ADDB1
SCHEMBL24462341 0.87 DDB1 (0.59) KDM2BWNT1GSK3BDYRK1ADDB1
SCHEMBL20951194 0.84 WNT1 (0.49) KDM2BWNT1GSK3BDYRK1ADDB1
SCHEMBL23048583 0.77 WNT1 (0.41) KDM2BWNT1GSK3BDYRK1AALDH1A1
SCHEMBL19546938 0.74 WNT1 (0.39) KDM2BWNT1GSK3BDYRK1A
SCHEMBL25390798 0.74 DDB1 (0.44) DDB1CRBNKDM4CKDM4EKDM5C
SCHEMBL24473911 0.73 DDB1 (0.62) WNT1GSK3BDYRK1ADDB1CRBN
SCHEMBL24462087 0.73 HCRTR2 (0.56) WNT1GSK3BDYRK1ADDB1CRBN
SCHEMBL29551148 0.73 HCRTR2 (0.56) WNT1GSK3BDYRK1ADDB1CRBN
SCHEMBL23280356 0.73 KDM2B (0.54) KDM2BWNT1GSK3BDYRK1AJMJD6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-07-07 — — US disclosed
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-07-07 — — US disclosed
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-05-02 — — US disclosed
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-05-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127370-A1 DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, DKK1, WNT1 KDM2B 2459/4885WNT1 3/4885GSK3B 19/4885
US-10703748-B2 Diazanaphthalen-3-yl carboxamides and preparation and use thereof DYRK1A, DKK1, WNT1 KDM2B 2459/4885WNT1 3/4885GSK3B 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback